DOCSLIB.ORG

SUPPLEMENTARY DATA Supplementary Figure 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SUPPLEMENTARY DATA Supplementary Figure 1 SUPPLEMENTARY DATA Supplementary Figure 1. Flowchart of study population. IA Negative: individuals who were never persistently positive for any islet autoantibody; IA Positive: individuals who had one or more persistently positive islet autoantibodies; Type 1 diabetes: diagnosed by ADA criteria between 1994 and 2011; AbPos: Antibody positive group; T1D: type 1 diabetes group. ©2019 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-1263/-/DC1 SUPPLEMENTARY DATA Supplementary Figure 2. Description of Repeated Optimization for Feature Interpretation with Posterior Probability Product (ROFI-P3) Algorithm. ©2019 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-1263/-/DC1 SUPPLEMENTARY DATA Supplementary Figure 3. Average Area Under the Receiver Operating Characteristic Curve (AUC) based on 5-fold cross-validation repeated 100 times for each data source and machine learning classification method. Outlined by a box are the maximum average AUC values selected for each of the six datasets across seven machine learning algorithms for two disease stages: (A) seroconversion and (B) progression to diabetes. This was the optimal machine learning algorithm. Methods used: RF: Random Forest; KNN: K-Nearest Neighbors; LDA: Linear Discriminant Analysis; LR: Logistic Regression; SVM (RBF): Support Vector Machine with a radial basis function kernel, SVM (LIN): SVM with a linear kernel; and NB: Naïve Bayes. ©2019 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-1263/-/DC1 SUPPLEMENTARY DATA Supplementary Figure 4. Number of features from each data stream retained at 50% selection for (A) Development of IA and (B) Progression from IA to diabetes Data Stream Data Data Stream Data ©2019 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-1263/-/DC1 SUPPLEMENTARY DATA Supplementary Table 1. Raw data for age and islet autoantibody status for control, islet autoantibody positive (AbPos) and type 1 diabetes (T1D) groups. Age and islet autoantibody status (1=positive, 0=negative) are given for each time point. Serum autoantibodies were measured for insulin (IAA), glutamic acid decarboxylase (GADA), insulinoma-associated protein 2 (IA-2A) and zinc transporter 8 (ZnT8A). Group randomID Timepoint Age (years) GADA IA-2A IAA ZnT8A Control 11010 T1 0.8 0 0 0 T2 3.0 0 0 0 T3 6.0 0 0 0 T4 12.0 0 0 0 Last 19.0 0 0 0 Control 13063 T1 0.8 0 0 0 T2 2.3 0 0 0 T3 4.3 0 0 0 T4/Last 6.8 0 0 0 0 Control 21580 T1 0.7 0 0 0 T2 7.5 0 0 0 T3 9.3 0 0 0 T4/Last 13.4 0 0 0 Control 21645 T1 0.7 0 0 0 T2 3.0 0 0 0 T3 5.2 0 0 0 T4/Last 8.2 0 0 0 0 ©2019 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-1263/-/DC1 SUPPLEMENTARY DATA Control 24684 T1 0.8 0 0 0 T2 2.1 0 0 0 T3 9.1 0 0 0 T4 12.1 0 0 0 Last 18.8 0 0 0 Control 28102 T1 0.7 0 0 0 T2 4.2 0 0 0 T3 7.6 0 0 0 T4/Last 16.1 0 0 0 Control 28410 T1 1.9 0 0 0 T2 5.1 0 0 0 T3 6.1 0 0 0 T4 7.2 0 0 0 0 Last 14.0 0 0 0 Control 31888 T1 0.7 0 0 0 T2 4.3 0 0 0 T3 6.3 0 0 0 T4 11.8 0 0 0 Last 19.2 0 0 0 Control 35055 T1 0.7 0 0 0 T2 3.0 0 0 0 ©2019 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-1263/-/DC1 SUPPLEMENTARY DATA T3 8.0 0 0 0 T4 16.0 0 0 0 Last 18.9 0 0 0 Control 38964 T1 0.8 0 0 0 T2 1.3 0 0 0 T3 2.1 0 0 0 T4 11.1 0 0 0 Last 18.5 0 0 0 Control 44935 T1 0.8 0 0 0 T2 2.0 0 0 0 T3 4.2 0 0 0 T4 6.9 0 0 0 Last 12.8 0 0 0 Control 51884 T1 1.2 0 0 0 T2 2.0 0 0 0 T3 3.1 0 0 0 T4/Last 4.1 0 0 0 0 Control 54642 T1 0.7 0 0 0 T2 2.0 0 0 0 T3 4.0 0 0 0 T4/Last 8.8 0 0 0 0 Control 57003 ©2019 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-1263/-/DC1 SUPPLEMENTARY DATA T1 1.3 0 0 0 T2 5.4 0 0 0 T3 11.5 0 0 0 T4 15.5 0 0 0 Last 17.5 0 0 0 0 Control 57732 T1 0.8 0 0 0 T2 1.3 0 0 0 T3 2.1 0 0 0 T4 3.1 0 0 0 0 Last 9.2 0 0 0 Control 61032 T1 0.9 0 0 0 T2 1.5 0 0 0 T3 2.0 0 0 0 T4 4.1 0 0 0 0 Last 16.3 0 0 0 Control 62568 T1 2.0 0 0 0 T2 4.5 0 0 0 T3 6.6 0 0 0 T4 7.6 0 0 0 Last 11.8 0 0 0 0 Control 66029 T1 1.2 0 0 0 T2 3.0 0 0 0 ©2019 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-1263/-/DC1 SUPPLEMENTARY DATA T3 7.1 0 0 0 T4 16.1 0 0 0 Last 23.0 0 0 0 Control 74515 T1 0.8 0 0 0 T2 3.2 0 0 0 T3 6.5 0 0 0 T4 12.1 0 0 0 Last 17.4 0 0 0 Control 81324 T1 0.7 0 0 0 T2 2.0 0 0 0 T3 4.2 0 0 0 0 T4 6.5 0 0 0 Last 14.8 0 0 0 Control 90948 T1 0.8 0 0 0 T2 6.1 0 0 0 T3 9.1 0 0 0 T4 16.0 0 0 0 Last 21.5 0 0 0 Control 92568 T1 0.8 0 0 0 T2 5.4 0 0 0 T3 8.7 0 0 0 T4 13.9 0 0 0 ©2019 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-1263/-/DC1 SUPPLEMENTARY DATA Last 17.6 0 0 0 Control 95491 T1 0.9 0 0 0 T2 6.0 0 0 0 T3 8.0 0 0 0 T4/Last 15.0 0 0 0 Control 98695 T1 0.7 0 0 0 T2 5.1 0 0 0 T3 9.4 0 0 0 T4 15.4 0 0 0 Last 22.5 0 0 0 Control 99949 T1 0.8 0 0 0 T2 5.2 0 0 0 T3 8.2 0 0 0 T4 14.1 0 0 0 Last 18.6 0 0 0 AbPos 10929 T1 0.8 0 0 0 0 T2 4.3 0 0 0 0 IA 5.3 1 0 0 0 T3 6.6 1 0 0 0 T4 17.0 1 1 0 Last 23.4 1 1 0 0 AbPos 12712 ©2019 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-1263/-/DC1 SUPPLEMENTARY DATA T1 1.4 0 0 0 T2 3.8 0 0 0 IA 5.8 1 0 0 T3 6.0 1 0 1 T4 6.5 1 0 1 Last 10.0 1 1 1 0 AbPos 15560 T1 0.8 0 0 0 T2 5.0 0 0 0 0 IA 6.0 0 0 1 T3 6.7 0 0 0 1 T4 8.6 1 1 1 Last 14.9 1 1 0 1 AbPos 18895 T1 0.9 0 0 0 T2 5.5 0 0 0 IA 10.1 0 1 0 1 T3 10.2 0 1 0 1 T4 12.0 1 1 0 Last 18.1 0 1 0 1 AbPos 28916 T1 1.3 0 0 0 0 T2 7.3 0 0 0 0 IA 8.3 0 0 0 1 T3 9.3 0 0 0 1 T4 15.2 1 1 0 ©2019 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-1263/-/DC1 SUPPLEMENTARY DATA Last 19.9 0 1 0 1 AbPos 33999 T1 0.7 0 0 0 0 T2 3.1 0 0 0 0 IA 7.9 1 0 1 0 T3 8.1 1 0 1 0 T4 15.7 1 0 0 Last 21.6 1 0 0 0 AbPos 44628 T1 0.8 0 0 0 0 T2 2.0 0 0 0 0 IA 3.0 1 0 1 1 T3 3.1 1 0 1 1 T4 9.1 1 1 1 Last 14.2 1 1 1 1 AbPos 54078 T1 3.5 0 0 0 0 T2 5.5 0 0 0 0 IA 7.4 0 0 0 1 T3 10.3 1 0 0 0 T4 14.1 1 1 0 Last 19.9 1 1 0 0 AbPos 66191 T1 2.1 0 0 0 T2 11.0 0 0 0 0 IA 12.0 1 0 1 0 ©2019 American Diabetes Association.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0346364 A1 BRUNS Et Al
    US 2016.0346364A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0346364 A1 BRUNS et al. (43) Pub. Date: Dec. 1, 2016 (54) MEDICAMENT AND METHOD FOR (52) U.S. Cl. TREATING INNATE IMMUNE RESPONSE CPC ........... A61K 38/488 (2013.01); A61K 38/482 DISEASES (2013.01); C12Y 304/23019 (2013.01); C12Y 304/21026 (2013.01); C12Y 304/23018 (71) Applicant: DSM IPASSETS B.V., Heerlen (NL) (2013.01); A61K 9/0053 (2013.01); C12N 9/62 (2013.01); A23L 29/06 (2016.08); A2ID 8/042 (72) Inventors: Maaike Johanna BRUINS, Kaiseraugst (2013.01); A23L 5/25 (2016.08); A23V (CH); Luppo EDENS, Kaiseraugst 2002/00 (2013.01) (CH); Lenneke NAN, Kaiseraugst (CH) (57) ABSTRACT (21) Appl. No.: 15/101,630 This invention relates to a medicament or a dietary Supple (22) PCT Filed: Dec. 11, 2014 ment comprising the Aspergillus niger aspergilloglutamic peptidase that is capable of hydrolyzing plant food allergens, (86). PCT No.: PCT/EP2014/077355 and more particularly, alpha-amylase/trypsin inhibitors, thereby treating diseases due to an innate immune response S 371 (c)(1), in humans, and/or allowing to delay the onset of said (2) Date: Jun. 3, 2016 diseases. The present invention relates to the discovery that (30) Foreign Application Priority Data the Aspergillus niger aspergilloglutamic peptidase is capable of hydrolyzing alpha-amylase/trypsin inhibitors that are Dec. 11, 2013 (EP) .................................. 13196580.8 present in wheat and related cereals said inhibitors being strong inducers of innate immune response. Furthermore, Publication Classification the present invention relates to a method for hydrolyzing alpha-amylase/trypsin inhibitors comprising incubating a (51) Int.
    [Show full text]
  • Clinical Study High Complement Factor I Activity in the Plasma of Children with Autism Spectrum Disorders
    Hindawi Publishing Corporation Autism Research and Treatment Volume 2012, Article ID 868576, 6 pages doi:10.1155/2012/868576 Clinical Study High Complement Factor I Activity in the Plasma of Children with Autism Spectrum Disorders Naghi Momeni,1 Lars Brudin,2 Fatemeh Behnia,3 Berit Nordstrom,¨ 4 Ali Yosefi-Oudarji,5 Bengt Sivberg,4 Mohammad T. Joghataei,5 and Bengt L. Persson1 1 School of Natural Sciences, Linnaeus University, 39182 Kalmar, Sweden 2 Department of Clinical Physiology, Kalmar County Hospital, 39185 Kalmar, Sweden 3 Department of Occupational Therapy, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran 4 Department of Health Sciences, Autism Research, Faculty of Medicine, Lund University, Box 157, 22100 Lund, Sweden 5 Cellular and Molecular Research Centre, Tehran University of Medical Sciences (TUMS), Tehran, Iran Correspondence should be addressed to Bengt Sivberg, [email protected] Received 17 June 2011; Revised 22 August 2011; Accepted 22 August 2011 Academic Editor: Judy Van de Water Copyright © 2012 Naghi Momeni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Autism spectrum disorders (ASDs) are neurodevelopmental and behavioural syndromes affecting social orientation, behaviour, and communication that can be classified as developmental disorders. ASD is also associated with immune system abnormality. Im- mune system abnormalities may be caused partly by complement system factor I deficiency. Complement factor I is a serine pro- tease present in human plasma that is involved in the degradation of complement protein C3b, which is a major opsonin of the complement system.
    [Show full text]
  • Mouse Prolyl Endopeptidase / PREP Protein (His Tag)
    Mouse Prolyl endopeptidase / PREP Protein (His Tag) Catalog Number: 50288-M07B General Information SDS-PAGE: Gene Name Synonym: AI047692; AI450383; D10Wsu136e; PEP; Pop Protein Construction: A DNA sequence encoding the mature form of mouse PREP (Q9QUR6) (Leu2-Gln710) was expressed, with a polyhistidine tag at the N-terminus. Source: Mouse Expression Host: Baculovirus-Insect Cells QC Testing Purity: > 95 % as determined by SDS-PAGE Endotoxin: Protein Description < 1.0 EU per μg of the protein as determined by the LAL method Prolyl endopeptidase, also known as PREP, belongs to a distinct class of Stability: serine peptidases. It is a large cytosolic enzyme which was first described in the cytosol of rabbit brain as an oligopeptidase. Prolyl endopeptidase ℃ Samples are stable for up to twelve months from date of receipt at -70 degrades the nonapeptide bradykinin at the Pro-Phe bond. It is involved in the maturation and degradation of peptide hormones and neuropeptides His Predicted N terminal: such as alpha-melanocyte-stimulating hormone, luteinizing hormone- Molecular Mass: releasing hormone (LH-RH), thyrotropin-releasing hormone, angiotensin, neurotensin, oxytocin, substance P and vasopressin. Prolyl The recombinant mouse PREP consists of 727 amino acids and predicts a endopeptidase's activity is confined to action on oligopeptides of less than molecular mass of 82.9 KDa. It migrates as an approximately 79-83 KDa 10 kD and it has an absolute requirement for the trans-configuration of the band in SDS-PAGE under reducing conditions. peptide bond preceding proline. It cleaves peptide bonds at the C-terminal side of proline residues. Formulation: References Lyophilized from sterile 20mM Tris, 500mM NaCl, pH 7.4, 10% glycerol, 3mM DTT 1.Oliveira EB, et al.
    [Show full text]
  • Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases
    International Journal of Molecular Sciences Review Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases Peter Goettig Structural Biology Group, Faculty of Molecular Biology, University of Salzburg, Billrothstrasse 11, 5020 Salzburg, Austria; [email protected]; Tel.: +43-662-8044-7283; Fax: +43-662-8044-7209 Academic Editor: Cheorl-Ho Kim Received: 30 July 2016; Accepted: 10 November 2016; Published: 25 November 2016 Abstract: Posttranslational modifications are an important feature of most proteases in higher organisms, such as the conversion of inactive zymogens into active proteases. To date, little information is available on the role of glycosylation and functional implications for secreted proteases. Besides a stabilizing effect and protection against proteolysis, several proteases show a significant influence of glycosylation on the catalytic activity. Glycans can alter the substrate recognition, the specificity and binding affinity, as well as the turnover rates. However, there is currently no known general pattern, since glycosylation can have both stimulating and inhibiting effects on activity. Thus, a comparative analysis of individual cases with sufficient enzyme kinetic and structural data is a first approach to describe mechanistic principles that govern the effects of glycosylation on the function of proteases. The understanding of glycan functions becomes highly significant in proteomic and glycomic studies, which demonstrated that cancer-associated proteases, such as kallikrein-related peptidase 3, exhibit strongly altered glycosylation patterns in pathological cases. Such findings can contribute to a variety of future biomedical applications. Keywords: secreted protease; sequon; N-glycosylation; O-glycosylation; core glycan; enzyme kinetics; substrate recognition; flexible loops; Michaelis constant; turnover number 1.
    [Show full text]
  • Reducing Immunoreactivity of Gliadins and Coeliac-Toxic Peptides Using Peptidases from L
    catalysts Article Reducing Immunoreactivity of Gliadins and Coeliac-Toxic Peptides Using Peptidases from L. acidophilus 5e2 and A. niger Bartosz Brzozowski *, Katarzyna Stasiewicz, Mateusz Ostolski and Marek Adamczak Department of Food Biotechnology, Faculty of Food Sciences, University of Warmia and Mazury in Olsztyn, 10-718 Olsztyn, Poland; [email protected] (K.S.); [email protected] (M.O.); [email protected] (M.A.) * Correspondence: [email protected] Received: 21 July 2020; Accepted: 10 August 2020; Published: 11 August 2020 Abstract: Wheat storage proteins and products of their hydrolysis may cause coeliac sprue in genetically predisposed individuals with high expression of main histocompatibility complex HLA-DQ2 or DQ8, since by consuming wheat, they become exposed to proline- (P) and glutamine (Q)-rich gluten. In bread-making, the hydrolysis of gliadins and coeliac-toxic peptides occurs with varied efficiency depending on the fermentation pH and temperature. Degradation of gliadins catalysed by Lactobacillus acidophilus 5e2 peptidases and a commercial prolyl endopeptidase synthesised by A. niger, carried out at pH 4.0 and 37 ◦C, reduces the gliadin concentration over 110-fold and decreases the relative immunoreactivity of the hydrolysate to 0.9% of its initial value. Hydrolysis of coeliac-toxic peptides: LGQQQPFPPQQPY (P1) and PQPQLPYPQPQLP (P2) under the same conditions occurs with the highest efficiency, reaching 99.8 0.0% and 97.5 0.1%, respectively. ± ± The relative immunoreactivity of peptides P1 and P2 was 0.8 0.0% and 3.2 0.0%, respectively. ± ± A mixture of peptidases from L. acidophilus 5e2 and A. niger may be used in wheat sourdough fermentation to reduce the time needed for degradation of proteins and products of their hydrolysis.
    [Show full text]
  • CDH12 Cadherin 12, Type 2 N-Cadherin 2 RPL5 Ribosomal
    5 6 6 5 . 4 2 1 1 1 2 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 A A A A A A A A A A A A A A A A A A A A C C C C C C C C C C C C C C C C C C C C R R R R R R R R R R R R R R R R R R R R B , B B B B B B B B B B B B B B B B B B B , 9 , , , , 4 , , 3 0 , , , , , , , , 6 2 , , 5 , 0 8 6 4 , 7 5 7 0 2 8 9 1 3 3 3 1 1 7 5 0 4 1 4 0 7 1 0 2 0 6 7 8 0 2 5 7 8 0 3 8 5 4 9 0 1 0 8 8 3 5 6 7 4 7 9 5 2 1 1 8 2 2 1 7 9 6 2 1 7 1 1 0 4 5 3 5 8 9 1 0 0 4 2 5 0 8 1 4 1 6 9 0 0 6 3 6 9 1 0 9 0 3 8 1 3 5 6 3 6 0 4 2 6 1 0 1 2 1 9 9 7 9 5 7 1 5 8 9 8 8 2 1 9 9 1 1 1 9 6 9 8 9 7 8 4 5 8 8 6 4 8 1 1 2 8 6 2 7 9 8 3 5 4 3 2 1 7 9 5 3 1 3 2 1 2 9 5 1 1 1 1 1 1 5 9 5 3 2 6 3 4 1 3 1 1 4 1 4 1 7 1 3 4 3 2 7 6 4 2 7 2 1 2 1 5 1 6 3 5 6 1 3 6 4 7 1 6 5 1 1 4 1 6 1 7 6 4 7 e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m
    [Show full text]
  • Supplementary Table 1: List of the 316 Genes Regulated During Hyperglycemic Euinsulinemic Clamp in Skeletal Muscle
    Supplementary Table 1: List of the 316 genes regulated during hyperglycemic euinsulinemic clamp in skeletal muscle. UGCluster Name Symbol Fold Change Cytoband Response to stress Hs.517581 Heme oxygenase (decycling) 1 HMOX1 3.80 22q12 Hs.374950 Metallothionein 1X MT1X 2.20 16q13 Hs.460867 Metallothionein 1B (functional) MT1B 1.70 16q13 Hs.148778 Oxidation resistance 1 OXR1 1.60 8q23 Hs.513626 Metallothionein 1F (functional) MT1F 1.47 16q13 Hs.534330 Metallothionein 2A MT2A 1.45 16q13 Hs.438462 Metallothionein 1H MT1H 1.42 16q13 Hs.523836 Glutathione S-transferase pi GSTP1 -1.74 11q13 Hs.459952 Stannin SNN -1.92 16p13 Immune response, cytokines & related Hs.478275 TNF (ligand) superfamily, member 10 (TRAIL) TNFSF10 1.58 3q26 Hs.278573 CD59 antigen p18-20 (protectin) CD59 1.49 11p13 Hs.534847 Complement component 4B, telomeric C4A 1.47 6p21.3 Hs.535668 Immunoglobulin lambda variable 6-57 IGLV6-57 1.40 22q11.2 Hs.529846 Calcium modulating ligand CAMLG -1.40 5q23 Hs.193516 B-cell CLL/lymphoma 10 BCL10 -1.40 1p22 Hs.840 Indoleamine-pyrrole 2,3 dioxygenase INDO -1.40 8p12-p11 Hs.201083 Mal, T-cell differentiation protein 2 MAL2 -1.44 Hs.522805 CD99 antigen-like 2 CD99L2 -1.45 Xq28 Hs.50002 Chemokine (C-C motif) ligand 19 CCL19 -1.45 9p13 Hs.350268 Interferon regulatory factor 2 binding protein 2 IRF2BP2 -1.47 1q42.3 Hs.567249 Contactin 1 CNTN1 -1.47 12q11-q12 Hs.132807 MHC class I mRNA fragment 3.8-1 3.8-1 -1.48 6p21.3 Hs.416925 Carcinoembryonic antigen-related cell adhesion molecule 19 CEACAM19 -1.49 19q13.31 Hs.89546 Selectin E (endothelial
    [Show full text]
  • Prolyl Endopeptidase from Aspergillus Niger Expressing A
    Annex 3 FORM ON WHICH INFORMATION ON THE COMPOUND TO BE EVALUATED BY JECFA IS PROVIDED In completing this form, only brief information is required. The form may be retyped if more space is needed under any one heading provided that the general format is maintained. Name of Compound(s): Acid prolyl endopeptidase from a genetically modified strain of Aspergillus niger Question(s) to be answered by JECFA Safety evaluation when used as processing aid. (kindly provide a brief justification of the request in case of re-evaluations) 1. Proposal for inclusion submitted by: Ministry of Health, Welfare and Sport Nutrition, Health Protection and Prevention Department Parnassusplein 5 2511 VX The Hague P.O. box 20350 2500 EJ The Hague The Netherlands Tel: +31 703407132 2. Name of compound; trade name(s); chemical name(s): Name of compound : Acid prolyl endopeptidase from a genetically modified strain of Aspergillus niger Trade names : BREWERS CLAREX®, MAXIPRO PSP Chemical name : Acid prolyl endopeptidase (EC 3.4.21.xx1) 3. Names and addresses of basic producers: DSM Food Specialties 15 Rue des Comtesses PO Box 239 59472 Seclin Cédex France Tel: 33 320964545 Fax: 33 320964500 4. Has the manufacturer made a commitment to provide data? Yes. 5. Identification of the manufacturer that will be providing data (Please indicate contact person): Dr Jack Reuvers 1 The name proline endopeptidase is also a synonym of prolyl oligopeptidase, EC (IUBMB) number 3.4.21.26. However, in contrast to oligopeptidases, the enzyme also acts on proteins (Edens et al., 2005; Kubota et al., 2005; Takahashi, 2013).
    [Show full text]
  • New Insights Into the Pathogenesis of Celiac Disease
    REVIEW published: 31 August 2017 doi: 10.3389/fmed.2017.00137 New Insights into the Pathogenesis of Celiac Disease Valli De Re 1*, Raffaella Magris2 and Renato Cannizzaro 2 1 Immunopatologia e Biomarcatori Oncologici/Bio-Proteomics Facility, CRO Aviano National Cancer Institute, Aviano, Italy, 2 Oncological Gastroenterology, CRO Aviano National Cancer Institute, Aviano, Italy Celiac disease (CD) is an autoimmune and multisystem gluten-related disorder that causes symptoms involving the gastrointestinal tract and other organs. Pathogenesis of CD is only partially known. It had been established that ingestion of gluten proteins present in wheat and other cereals are necessary for the disease and develops in individuals genetically predisposed carrying the DQ2 or DQ8 human leukocyte antigen haplotypes. In this review, we had pay specific attention on the last discoveries regarding the three cellular components mainly involved in the development and maintenance of CD: T-cells, B-cells, and microbioma. All of them had been showed critical for the interaction between inflammatory immune response and gluten peptides. Although the mechanisms of interaction among overall these components are not yet fully understood, recent proteomics and molecular studies had shed some lights in the pathogenic role of tissue transglutaminase 2 in CD and in the alteration of the intestinal barrier function Edited by: induced by host microbiota. Arun Chaudhury, GIM Foundation, Keywords: celiac disease, B-cell, immunoglobulin, transglutaminase, microbioma United States Reviewed by: INTRODUCTION Shashank Kraleti, University of Arkansas for Medical Celiac disease (CD) is characterized by small intestinal mucosal injury and nutrient malabsorption Sciences, United States (1). Studies of stored serum showed an increase in CD prevalence from fourfold to fivefold over Sumit Fogla, the past 50 years (2).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,524,654 B2 Blalock Et Al
    USOO8524654B2 (12) United States Patent (10) Patent No.: US 8,524,654 B2 Blalock et al. (45) Date of Patent: Sep. 3, 2013 (54) PROLYL ENDOPEPTIDASE INHIBITORS 5,506,256 A 4/1996 Kobayashi et al. FOR REDUCING OR PREVENTING SEF, A 3: byshi et al. ea. NEUTROPHILIC INFLAMMATION 5,756,763 A 5/1998 Takeuchi et al. 5,965,556 A 10/1999 Takeuchi et al. (75) Inventors: J. Edwin Blalock, Birmingham, AL 6,875,851 B1 4, 2005 kills a (US); Uros V. Djekic, Rockville, MD 6,878,751 B1* 4/2005 Donnelly et al. ............. 514,733 (US); Patricia L. Jackson, Moody, AL 2004.5. R 1238. ShingSorge etstal al. (US);S. BrettR SENoerager, ESN Birmingham, ALAL 2007/00213602005/0014699 A1 1/20071/2005 NyceAnsorge et al. et al. (US); Philip J. O'Reilly, Hoover, AL (US) FOREIGN PATENT DOCUMENTS EP O286928 4f1988 (73) Assignee: The UAB Research Foundation, EP O384341 8, 1990 Birmingham, AL (US) WO WO9012005 10, 1990 OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this Thorax, Aug. 1, 2007.vil 62, No. 8,706-713, published online on Feb. patent is extended or adjusted under 35 20, 2007.* U.S.C. 154(b) by 552 days. Marti et al., “Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characteriza (21) Appl. No.: 12/601,216 tion.” J. Pharmacol. Exp. Ther. 312:19-26 (2005). Matter et al., “Quantitative structure—activity relationship of human (22) PCT Filed: May 21, 2008 neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis.
    [Show full text]
  • Prolyl Endopeptidase Contributes to Early Neutrophilic Inflammation in Acute Myocardial Transplant Rejection
    RESEARCH ARTICLE Prolyl endopeptidase contributes to early neutrophilic inflammation in acute myocardial transplant rejection Gregory A. Payne,1,2,3,4,5 Nirmal S. Sharma,6,7 Charitharth V. Lal,4,8 Chunyan Song,1 Lingling Guo,9,10 Camilla Margaroli,4,11 Liliana Viera,4,11,12 Siva Kumar,6,13 Jindong Li,4,11 Dongqi Xing,2,4,11 Melanie Bosley,13 Xin Xu,4,11 J. Michael Wells,4,5,11,12 James F. George,9,10 Jose Tallaj,1,3 Massoud Leesar,1,3 J. Edwin Blalock,2,4,11,12,14 and Amit Gaggar2,4,5,11,12,14 1Division of Cardiovascular Disease, Department of Medicine, 2Vascular Biology and Hypertension Program, 3Comprehensive Cardiovascular Center, and 4Program in Protease and Matrix Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA. 5Medical Service at Birmingham VA Medical Center, Birmingham, Alabama, USA. 6Department of Internal Medicine, University of South Florida, Tampa, Florida, USA. 7Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA.8Division of Neonatology, Department of Pediatrics, 9Department of Surgery, 10Nephrology Research & Training Center, Division of Nephrology, Department of Medicine, 11Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, and 12Lung Health Center, University of Alabama at Birmingham, Birmingham, Alabama, USA. 13Tampa General Hospital, Tampa, Florida, USA. 14Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Altered inflammation and tissue remodeling are cardinal features of cardiovascular disease and cardiac transplant rejection. Neutrophils have increasingly been understood to play a critical role in acute rejection and early allograft failure; however, discrete mechanisms that drive this damage remain poorly understood.
    [Show full text]
  • Evaluation of Clinical Colon Carcinoma Using Activity-Based Proteomic Profiling Melissa C
    Clinical Proteomics Journal Copyright © Humana Press Inc. All rights of any nature whatsoever are reserved. ISSN 1542-6416/04/01:301–311/$25.00 Original Article Evaluation of Clinical Colon Carcinoma Using Activity-Based Proteomic Profiling Melissa C. Zhang,1 Jiangyue Wu,1 Kristin G. Ardlie,2 and Emme C. K. Lin1,∗ 1ActivX Biosciences, Inc., La Jolla, CA; and 2Genomics Collaborative, Inc., Cambridge, MA expression. We identified one tumor-specific Abstract activity by mass spectrometry to be fibroblast The evaluation of clinical tumor tissues is a activation protein (FAP), an integral membrane valuable approach to discovering novel drug serine protease that has been reported to be pre- targets because of the direct relevance of human sent only in tumor stroma or during wound samples. We used activity-based proteomic pro- healing and absent in normal tissues. FAP activ- filing (ABPP) to study the differences in serine ity was further found to be approximately hydrolase activities from 12 matched pairs of twofold higher in stage III relative to stage II clinical normal and tumor colon tissues. Unlike colon cancer, suggestive of a role in tumor pro- traditional proteomics or measures of mRNA gression. We were also able to identify other abundance, ABPP actually quantifies enzymatic proteins, some of which had not been previ- activities, a characteristic crucial for drug target- ously linked to cancer, which had higher activity ing. Several serine hydrolases were differentially in tumors. Our results demonstrate the applica- active in tumor vs normal tissues, despite a lack bility of ABPP for the efficient identification of of obvious corresponding alterations in protein multiple clinical disease targets.
    [Show full text]